Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Want to see STRO full AI Analyst Report?
STRO Stock Chart & Stats
$31.55
-$0.05(-2.48%)
At close: 4:00 PM EST
$31.55
-$0.05(-2.48%)
Day’s Range― - ―
52-Week Range$6.73 - $43.85
Previous CloseN/A
Volume326.60K
Average Volume (3M)987.85K
Market Cap
$477.23M
Enterprise Value$188.34M
Total Cash (Recent Filing)$202.56M
Total Debt (Recent Filing)$13.63M
Price to Earnings (P/E)―
Beta3.58
Next Earnings
Aug 10, 2026EPS Estimate
-2.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-307.72
Shares Outstanding16,570,438
10 Day Avg. Volume2,002,360
30 Day Avg. Volume987,852
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-0.74
Price to Sales (P/S)0.96
P/FCF Ratio-0.55
Enterprise Value/Market Cap0.39
Enterprise Value/Revenue1.89
Enterprise Value/Gross Profit1.92
Enterprise Value/Ebitda-1.77
Forecast
1Y Price Target
$48.60Price Target Upside54.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-8.72
Revenue Forecast (FY)$44.06M
Bulls Say, Bears Say
Bulls Say
Proprietary Cell-free PlatformSutro’s proprietary cell-free XpressCF platform is a durable technological asset that speeds protein design and production. Over months it supports competitive advantage in ADCs and engineered biologics, enabling faster iteration, partner collaborations, and potential recurring licensing revenue streams.
Very High Gross MarginsSustained ~98% gross margins indicate strong unit economics for platform services and potential productized outputs, suggesting scalable revenue from partnerships or future products. High gross margins provide structural leverage to improve profitability as R&D spending stabilizes or revenues grow.
Strengthened Near-term Financing And RunwayThe $110M equity raise and ATM termination materially extend runway into Q2 2028, reducing immediate financing pressure and dilution risk. This gives management time to advance multiple clinical and preclinical programs and pursue partner-triggered milestones without imminent cash constraints.
Bears Say
Heavy Cash BurnSustained negative operating and free cash flow (~-$152M TTM) shows structural cash consumption from R&D and operations. Over a multi-month horizon this elevates dependence on external capital and milestone receipts, constraining flexibility and raising execution risk if expected financings or partner payments slip.
Negative Shareholders' EquityA negative shareholders' equity balance (~-$66.9M) signals material balance-sheet erosion. This reduces financial cushion, can impair negotiating leverage with partners and licensors, and increases the likelihood of dilutive financings or restrictive covenants that could affect long-term strategic options.
Volatile, Contracting RevenueHighly volatile top-line and a ~281% TTM contraction demonstrate unreliable revenue pacing driven by milestone timing. Structurally, this unpredictability complicates multi-quarter planning, raises funding dependency, and limits visibility into when recurring or scalable revenue will offset ongoing R&D spend.
Sutro Biopharma News
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $6.73 and its highest was $43.85 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $477.23M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Aug 10, 2026 which is in 56 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on May 14, 2026. The company reported -$2.94 earnings per share for the quarter, missing the consensus estimate of -$2.736 by -$0.204.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -2.2.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 16,570,438 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$2.94 in its last earnings report, missing expectations of -$2.736. Following the earnings report the stock price went up 1.432%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sutro Biopharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$48.60 (54.04% Upside)
$48.60 (54.04% Upside)
Hedge Fund Trend
Increased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.6%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.43%
12-Months-Change
Fundamentals
Return on Equity
275.30%
Trailing 12-Months
Asset Growth
-24.72%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.
STRO Stock 12 Month Forecast
Average Price Target
$48.60
▲(54.04% Upside)
Technical Analysis
Ownership Overview
0.81% Insiders
10.89% Mutual Funds
59.34% Other Institutional Investors
24.49% Public Companies and
Individual Investors